Cromolyn Sodium for Treatment of COVID-19 Pneumonia

Status Recruiting

Clinical Trial Summary

The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life. Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pneumonia and who require supplemental oxygen. Cromolyn will be administered as a nebulized treatment four times a day for four days followed by intranasal administration for two weeks. Investigators may also screen for biomarkers that could indicate inflammatory responses and treatment-induced improvement. Participants will receive either study drug or placebo which will be administered by nebulization for 4 days followed by 14 days of intranasal administration. Participants will be followed while in the hospital and then as outpatients up to day 21 following randomization.

Clinical Trial Description

The study will take place in two phases: Phase 1 will be an open label study of 10 patients who will all receive the Cromolyn nebulization treatment followed by Cromolyn nasal spray to assess tolerability and response to the study treatment. Investigators may also draw blood from 10 healthy patients who will be the controls for the cellular and cytokine assays. Phase 2 will be a randomized double blind placebo-controlled study of 50 patients randomized 1:1 to receive Cromolyn nebulization followed by Cromolyn intranasal spray vs. saline nebulization and saline intranasal spray. While subjects are hospitalized, investigators will record morning pulse, respiratory rate and oxygen saturation. Morning and daily peak oxygen supplementation as indicated by the use of high flow nasal cannula, non-invasive ventilation, or invasive ventilation will be recorded. The investigators will also note any improvement or decline in participant's condition and any reduction or increase in oxygen supplementation. Follow-up phone calls (or EMR review if still hospitalized) will be made on days 7, 14, and 21 to assess dyspnea and physical function. Validated questionnaires from the Patient-Reported Outcomes Measurement Information System (PROMIS) (https://www.healthmeasures.net/explore-measurement-systems/promis) will be used to evaluate dyspnea and physical function. Once discharged, patients will also be asked to maintain a daily log of nasal drug use, COVID-19 symptoms, resting pulse and oxygen saturation which will be reviewed at the 21 day virtual visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05077917
Study type	Interventional
Source	Texas Tech University Health Sciences Center, El Paso
Contact	Susan Watts, PhD
Phone	(915) 215-4633
Email	Susan.Watts@ttuhsc.edu
Status	Recruiting
Phase	Phase 3
Start date	November 15, 2021
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT04901676` - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia	Phase 3
Not yet recruiting	`NCT04534478` - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19	Phase 4
Active, not recruiting	`NCT05002517` - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab	Phase 3
Completed	`NCT05008393` - Efficacy of PJS-539 for Adult Patients With COVID-19.	Phase 2
Completed	`NCT04569877` - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia	Phase 2
Not yet recruiting	`NCT05286255` - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias	Phase 1
Completed	`NCT05035589` - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Completed	`NCT06113432` - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study	N/A
Recruiting	`NCT05042063` - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting	`NCT04615429` - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19	Phase 2
Completed	`NCT05047653` - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting	`NCT05047016` - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY	N/A
Active, not recruiting	`NCT05033847` - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above	Phase 2
Recruiting	`NCT06113757` - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease	N/A
Completed	`NCT05504655` - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting	`NCT05035524` - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19	N/A
Completed	`NCT05065879` - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes	Phase 4
Withdrawn	`NCT04390217` - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia	Phase 2
Withdrawn	`NCT04460105` - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia	Phase 1
Suspended	`NCT04901689` - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation	Phase 3